Vly News - Professional news Platform

Coronavirus disease 2019 (COVID-19) is a viral respiratory tract infection that is responsible for various thrombotic events in major blood vessels in the human body, especially deep vein thrombosis (DVT) and pulmonary embolism. [1]. These thromboembolic events are thought to arise from an immune and pro-inflammatory response that results in the production of procoagulation factors that are responsible for vascular injury. Despite the predominant venous etiology, rare reports now implicate COVID-19 in adverse arterial events such as arterial thrombosis that can lead to acute limb ischemia (ALI). [1]. ALI is an emergent vascular event that results in decreased limb blood flow and subsequent tissue hypoperfusion [2]. This article was previously presented as a poster at Michigan State University State University Emergency Medicine Resident Case Report Poster Day on February 16, 2022, and at the Henry Ford Health Systems Medical Education Research Forum on April 1, 2021. A 69-year-old w

New cancer drug halves deaths in hospitalized COVID-19 patients The experimental cancer drug sabizabulin slashed all-cause mortality by 55.2% versus placebo in high-risk hospitalized COVID-19 patients for 60 days and was associated with fewer side effects, according to preliminary results from a published phase 3 randomized controlled trial. yesterday at NEJM Evidence . Scientists from sabizabulin manufacturer Veru, Inc. led a multicenter trial of the oral drug, which demonstrated antiviral and anti-inflammatory properties in a preclinical model. These drugs bind to microtubules that are essential for SARS-CoV-2 cell entry and replication and for the massive inflammatory response leading to acute respiratory distress syndrome (ARDS) and death. A total of 204 adults with moderate to severe COVID-19 at high risk for poor outcome were randomly assigned to receive 9 milligrams of sabizabulin or a placebo daily for up to 21 days. The trial was terminated early due to demonstrating drug e